J&J reports patient findings from Sjögren’s drug study
andreswd/E+ via Getty Images
Johnson & Johnson (JNJ) said new interviews with participants in a midstage study of nipocalimab identified mouth dryness as their leading priority for symptom improvement in Sjögren’s disease. The chronic condition causes the immune system to attack healthy tissue, often leading
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.